Belgium-based Janssen Pharmaceutical's Tremfya (guselkumab) was found to be superior to Cosentyx (secukinumab) for the primary endpoint evaluated at week 48 of a phase three trial in adults with moderate to severe plaque psoriasis, it was reported yesterday.
The phase 3 trial, called ECLIPSE, enrolled 1,048 patients to assess the efficacy and safety of Tremfya in comparison to Cosentyx. Tremfya is an interleukin (IL)-23-targeted biologic therapy and Cosentyx is an IL-17 inhibitor owned by Novartis.
The company revealed that 84.5% of patients, who were subjected to Tremfya, had indicated an improvement of around 90% in their baseline Psoriasis Area Severity Index (PASI) score at week 48. This was in comparison to 70% of patients on treatment with Cosentyx.
Tremfya is approved in the US and Europe or the treatment of adults with moderate to severe plaque psoriasis.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval